Guidelines for the management of adult lower respiratory tract infections - Summary

Woodhead, 2005, Guidelines for the management of adult lower respiratory tract infections, Eur Respir J, 26, 1138, 10.1183/09031936.05.00055705 American Thoracic Society, 2005, Guidelines for the management of adults with hospital‐acquired, ventilator‐associated, and healthcare‐associated pneumonia, Am J Respir Crit Care Med, 171, 388, 10.1164/rccm.200405-644ST Kollef, 2005, Epidemiology and outcomes of health‐care‐associated pneumonia: results from a large US database of culture‐positive pneumonia, Chest, 128, 3854, 10.1378/chest.128.6.3854 Micek, 2007, Health care‐associated pneumonia and community‐acquired pneumonia: a single‐center experience, Antimicrob Agents Chemother, 51, 3568, 10.1128/AAC.00851-07 El Solh, 2004, Indicators of potentially drug‐resistant bacteria in severe nursing home‐acquired pneumonia, Clin Infect Dis, 39, 474, 10.1086/422317 El‐Solh, 2003, Microbiology of severe aspiration pneumonia in institutionalized elderly, Am J Respir Crit Care Med, 167, 1650, 10.1164/rccm.200212-1543OC Carratala, 2007, Health care‐associated pneumonia requiring hospital admission: epidemiology, antibiotic therapy, and clinical outcomes, Arch Intern Med, 167, 1393, 10.1001/archinte.167.13.1393 Garb, 1978, Differences in etiology of pneumonias in nursing home and community patients, JAMA, 240, 2169, 10.1001/jama.1978.03290200047020 Lim, 2001, A prospective comparison of nursing home acquired pneumonia with community acquired pneumonia, Eur Respir J, 18, 362, 10.1183/09031936.01.00204401 Marrie, 1997, A comparison of nursing home‐acquired pneumonia patients with patients with community‐acquired pneumonia and nursing home patients without pneumonia, J Am Geriatr Soc, 45, 50, 10.1111/j.1532-5415.1997.tb00977.x Meehan, 2000, Process of care performance, patient characteristics, and outcomes in elderly patients hospitalized with community‐acquired or nursing home‐acquired pneumonia, Chest, 117, 1378, 10.1378/chest.117.5.1378 Naughton, 2001, Antibiotic use, hospital admissions, and mortality before and after implementing guidelines for nursing home‐acquired pneumonia, J Am Geriatr Soc, 49, 1020, 10.1046/j.1532-5415.2001.49203.x Shindo, 2009, Health‐care‐associated pneumonia among hospitalized patients in a Japanese community hospital, Chest, 135, 633, 10.1378/chest.08-1357 Shorr, 2008, Prediction of infection due to antibiotic‐resistant bacteria by select risk factors for health care‐associated pneumonia, Arch Intern Med, 168, 2205, 10.1001/archinte.168.20.2205 Venditti, 2009, Outcomes of patients hospitalized with community‐acquired, health care‐associated, and hospital‐acquired pneumonia, Ann Intern Med, 150, 19, 10.7326/0003-4819-150-1-200901060-00005 Webster, 2007, Health care‐associatedStaphylococcus aureus pneumonia, Can J Infect Dis Med Microbiol, 18, 181, 10.1155/2007/136796 Zilberberg, 2008, Antimicrobial therapy escalation and hospital mortality among patients with health‐care‐associated pneumonia: a single‐center experience, Chest, 134, 963, 10.1378/chest.08-0842 Johansson, 2010, Etiology of community‐acquired pneumonia: increased microbiological yield with new diagnostic methods, Clin Infect Dis, 50, 202, 10.1086/648678 Ewig, 2002, Factors associated with unknown aetiology in patients with community‐acquired pneumonia, Eur Respir J, 20, 1254, 10.1183/09031936.02.01942001 Korppi, 2002, Mixed microbial aetiology of community‐acquired pneumonia in children, APMIS, 110, 515, 10.1034/j.1600-0463.2002.11007801.x Gutierrez, 2005, Community‐acquired pneumonia of mixed etiology: prevalence, clinical characteristics, and outcome, Eur J Clin Microbiol Infect Dis, 24, 377, 10.1007/s10096-005-1346-2 de, 2004, Viral community‐acquired pneumonia in nonimmunocompromised adults, Chest, 125, 1343, 10.1378/chest.125.4.1343 Angeles, 2006, The role of viruses in the aetiology of community‐acquired pneumonia in adults, Antivir Ther, 11, 351, 10.1177/135965350601100306 Lauderdale, 2005, Etiology of community acquired pneumonia among adult patients requiring hospitalization in Taiwan, Respir Med, 99, 1079, 10.1016/j.rmed.2005.02.026 Wattanathum, 2003, Community‐acquired pneumonia in southeast Asia: the microbial differences between ambulatory and hospitalized patients, Chest, 123, 1512, 10.1378/chest.123.5.1512 Saito, 2006, Prospective multicenter study of the causative organisms of community‐acquired pneumonia in adults in Japan, J Infect Chemother, 12, 63, 10.1007/s10156-005-0425-8 Jennings, 2008, Incidence and characteristics of viral community‐acquired pneumonia in adults, Thorax, 63, 42, 10.1136/thx.2006.075077 Song, 2008, Epidemiology and clinical outcomes of community‐acquired pneumonia in adult patients in Asian countries: a prospective study by the Asian network for surveillance of resistant pathogens, Int J Antimicrob Agents, 31, 107, 10.1016/j.ijantimicag.2007.09.014 de, 2006, Mixed community‐acquired pneumonia in hospitalised patients, Eur Respir J, 27, 795, 10.1183/09031936.06.00058605 Centers for Disease Control (CDC), 2009, Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1) ‐ United States, May–August 2009, MMWR Morb Mortal Wkly Rep, 58, 1071 Almirall, 2000, Epidemiology of community‐acquired pneumonia in adults: a population‐based study, Eur Respir J, 15, 757, 10.1034/j.1399-3003.2000.15d21.x Anzueto, 1998, Etiology, susceptibility, and treatment of acute bacterial exacerbations of complicated chronic bronchitis in the primary care setting: ciprofloxacin 750 mg b.i.d. versus clarithromycin 500 mg b.i.d. Bronchitis Study Group, Clin Ther, 20, 885, 10.1016/S0149-2918(98)80071-4 Blasi, 1995, Emerging pathogens of community‐acquired pneumonia: a two‐year prospective study, J Chemother, 7, 115 Bohte, 1995, Aetiology of community‐acquired pneumonia: a prospective study among adults requiring admission to hospital, Thorax, 50, 543, 10.1136/thx.50.5.543 Brandenburg, 2000, Clinical presentation, processes and outcomes of care for patients with pneumococcal pneumonia, J Gen Intern Med, 15, 638, 10.1046/j.1525-1497.2000.04429.x El Solh, 2001, Etiology of severe pneumonia in the very elderly, Am J Respir Crit Care Med, 163, 645, 10.1164/ajrccm.163.3.2005075 Ginesu, 1997, Etiology and therapy of community‐acquired pneumonia, J Chemother, 9, 285, 10.1179/joc.1997.9.4.285 Gomez, 1996, Prospective study of epidemiology and prognostic factors in community‐acquired pneumonia, Eur J Clin Microbiol Infect Dis, 15, 556, 10.1007/BF01709363 Gowardman, 2000, Severe community acquired pneumonia: a one‐year analysis in a tertiary referral intensive care unit, N Z Med J, 113, 161 Hedlund, 1997, Recurrence of pneumonia in middle‐aged and elderly adults after hospital‐treated pneumonia: aetiology and predisposing conditions, Scand J Infect Dis, 29, 387, 10.3109/00365549709011836 Hirani, 1997, Impact of management guidelines on the outcome of severe community acquired pneumonia, Thorax, 52, 17, 10.1136/thx.52.1.17 Jokinen, 2001, Microbial etiology of community‐acquired pneumonia in the adult population of 4 municipalities in eastern Finland, Clin Infect Dis, 32, 1141, 10.1086/319746 Jones, 2000, Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997), Diagn Microbiol Infect Dis, 37, 115, 10.1016/S0732-8893(00)00115-2 Leroy, 1997, Community‐acquired aspiration pneumonia in intensive care units. Epidemiological and prognosis data, Am J Respir Crit Care Med, 156, 1922, 10.1164/ajrccm.156.6.9702069 Leroy, 1999, Community‐acquired pneumonia in the intensive care unit: epidemiological and prognosis data in older people, J Am Geriatr Soc, 47, 539, 10.1111/j.1532-5415.1999.tb02567.x Logroscino, 1999, Community‐acquired pneumonia in adults: a multicentric observational AIPO study, Monaldi Arch Chest Dis, 54, 11 Lorente, 2000, Diagnosis of pneumococcal pneumonia by polymerase chain reaction (PCR) in whole blood: a prospective clinical study, Thorax, 55, 133, 10.1136/thorax.55.2.133 Lim, 2001, Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines, Thorax, 56, 296, 10.1136/thorax.56.4.296 Marrie, 1996, Ambulatory patients with community‐acquired pneumonia: the frequency of atypical agents and clinical course, Am J Med, 101, 508, 10.1016/S0002-9343(96)00255-0 Meijer, 2000, Low prevalence ofChlamydia pneumoniae andMycoplasma pneumoniae among patients with symptoms of respiratory tract infections in Dutch general practices, Eur J Epidemiol, 16, 1099, 10.1023/A:1010912012932 Menendez, 1999, Value of the polymerase chain reaction assay in noninvasive respiratory samples for diagnosis of community‐acquired pneumonia, Am J Respir Crit Care Med, 159, 1868, 10.1164/ajrccm.159.6.9807070 Michetti, 1995, Community‐acquired pneumonia: is there difference in etiology between hospitalized and out‐patients?, Minerva Med, 86, 341 Olaechea, 1996, A predictive model for the treatment approach to community‐acquired pneumonia in patients needing ICU admission, Intensive Care Med, 22, 1294, 10.1007/BF01709541 Ruiz, 1999, Etiology of community‐acquired pneumonia: impact of age, comorbidity, and severity, Am J Respir Crit Care Med, 160, 397, 10.1164/ajrccm.160.2.9808045 Socan, 1999, Microbial aetiology of community‐acquired pneumonia in hospitalised patients, Eur J Clin Microbiol Infect Dis, 18, 777, 10.1007/s100960050400 Sopena, 1999, Prospective study of community‐acquired pneumonia of bacterial etiology in adults, Eur J Clin Microbiol Infect Dis, 18, 852, 10.1007/s100960050419 Steinhoff, 1996, Chlamydia pneumoniae as a cause of community‐acquired pneumonia in hospitalized patients in Berlin, Clin Infect Dis, 22, 958, 10.1093/clinids/22.6.958 Garcia‐Vidal, 2009, Aetiology of, and risk factors for, recurrent community‐acquired pneumonia, Clin Microbiol Infect, 15, 1033, 10.1111/j.1469-0691.2009.02918.x Berglund, 2005, Predominance of staphylococcal cassette chromosome mec (SCCmec) type IV among methicillin‐resistantStaphylococcus aureus (MRSA) in a Swedish county and presence of unknown SCCmec types with Panton‐Valentine leukocidin genes, Clin Microbiol Infect, 11, 447, 10.1111/j.1469-0691.2005.01150.x Gillet, 2002, Association betweenStaphylococcus aureus strains carrying gene for Panton‐Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients, Lancet, 359, 753, 10.1016/S0140-6736(02)07877-7 Hageman, 2006, Severe community‐acquired pneumonia due toStaphylococcus aureus, 2003–04 influenza season, Emerg Infect Dis, 12, 894, 10.3201/eid1206.051141 Lina, 1999, Involvement of Panton‐Valentine leukocidin‐producingStaphylococcus aureus in primary skin infections and pneumonia, Clin Infect Dis, 29, 1128, 10.1086/313461 Davis, 2007, Epidemiology and outcomes of community‐associated methicillin‐resistantStaphylococcus aureus infection, J Clin Microbiol, 45, 1705, 10.1128/JCM.02311-06 Creer, 2006, Aetiological role of viral and bacterial infections in acute adult lower respiratory tract infection (LRTI) in primary care, Thorax, 61, 75, 10.1136/thx.2004.027441 Flamaing, 2003, Viral lower respiratory tract infection in the elderly: a prospective in‐hospital study, Eur J Clin Microbiol Infect Dis, 22, 720, 10.1007/s10096-003-1042-z Johnstone, 2008, Viral infection in adults hospitalized with community‐acquired pneumonia: prevalence, pathogens, and presentation, Chest, 134, 1141, 10.1378/chest.08-0888 Beigel, 2005, Avian influenza A (H5N1) infection in humans, N Engl J Med, 353, 1374, 10.1056/NEJMra052211 Chotpitayasunondh, 2005, Human disease from influenza A (H5N1), Thailand, 2004, Emerg Infect Dis, 11, 201, 10.3201/eid1102.041061 Miedzinski, 2005, Community‐acquired pneumonia: new facets of an old disease – Hantavirus pulmonary syndrome, Respir Care Clin N Am, 11, 45, 10.1016/j.rcc.2004.10.003 Patrick, 2006, An outbreak of human Coronavirus OC43 infection and serological cross‐reactivity with SARS Coronavirus, Can J Infect Dis Med Microbiol, 17, 330, 10.1155/2006/152612 Drosten, 2003, Identification of a novel coronavirus in patients with severe acute respiratory syndrome, N Engl J Med, 348, 1967, 10.1056/NEJMoa030747 Chowell, 2009, Severe respiratory disease concurrent with the circulation of H1N1 influenza, N Engl J Med, 361, 674, 10.1056/NEJMoa0904023 Gutierrez, 2006, The influence of age and gender on the population‐based incidence of community‐acquired pneumonia caused by different microbial pathogens, J Infect, 53, 166, 10.1016/j.jinf.2005.11.006 Ingarfield, 2007, The bacteriology of pneumonia diagnosed in Western Australian emergency departments, Epidemiol Infect, 135, 1376, 10.1017/S0950268807007844 Eller, 1998, Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function, Chest, 113, 1542, 10.1378/chest.113.6.1542 Miravitlles, 1999, Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD, Chest, 116, 40, 10.1378/chest.116.1.40 Alamoudi, 2007, Bacterial infection and risk factors in outpatients with acute exacerbation of chronic obstructive pulmonary disease: a 2‐year prospective study, Respirology, 12, 283, 10.1111/j.1440-1843.2006.01002.x McManus, 2008, Respiratory viral infection in exacerbations of COPD, Respir Med, 102, 1575, 10.1016/j.rmed.2008.06.006 Roche, 2007, Yield of sputum microbiological examination in patients hospitalized for exacerbations of chronic obstructive pulmonary disease with purulent sputum, Respiration, 74, 19, 10.1159/000093158 Hutchinson, 2007, A community‐based, time‐matched, case‐control study of respiratory viruses and exacerbations of COPD, Respir Med, 101, 2472, 10.1016/j.rmed.2007.07.015 Diederen, 2007, The role of atypical respiratory pathogens in exacerbations of chronic obstructive pulmonary disease, Eur Respir J, 30, 240, 10.1183/09031936.00012707 Ko, 2007, A 1‐year prospective study of the infectious etiology in patients hospitalized with acute exacerbations of COPD, Chest, 131, 44, 10.1378/chest.06-1355 Monso, 2003, Bacterial infection in exacerbated COPD with changes in sputum characteristics, Epidemiol Infect, 131, 799, 10.1017/S0950268803008872 Murphy, 2008, Pseudomonas aeruginosa in chronic obstructive pulmonary disease, Am J Respir Crit Care Med, 177, 853, 10.1164/rccm.200709-1413OC Lieberman, 2002, Pneumonic vs nonpneumonic acute exacerbations of COPD, Chest, 122, 1264, 10.1378/chest.122.4.1264 Buscho, 1978, Infections with viruses andMycoplasma pneumoniae during exacerbations of chronic bronchitis, J Infect Dis, 137, 377, 10.1093/infdis/137.4.377 Sethi, 2002, New strains of bacteria and exacerbations of chronic obstructive pulmonary disease, N Engl J Med, 347, 465, 10.1056/NEJMoa012561 Angrill, 2002, Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors, Thorax, 57, 15, 10.1136/thorax.57.1.15 Ho, 1998, The effect ofPseudomonas aeruginosa infection on clinical parameters in steady‐state bronchiectasis, Chest, 114, 1594, 10.1378/chest.114.6.1594 van der, 2010, Q fever in the Netherlands: an update on the epidemiology and control measures, Euro Surveill, 15, 1 Spratt, 1975, Penicillin‐binding proteins and cell shape inE. coli, Nature, 254, 516, 10.1038/254516a0 Doit, 1999, Emergence in france of multiple clones of clinicalStreptococcus pneumoniae isolates with high‐level resistance to amoxicillin, Antimicrob Agents Chemother, 43, 1480, 10.1128/AAC.43.6.1480 Carratala, 1997, Treatment of penicillin‐resistant pneumococcal bacteremia in neutropenic patients with cancer, Clin Infect Dis, 24, 148, 10.1093/clinids/24.2.148 Yu, 2003, An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome, Clin Infect Dis, 37, 230, 10.1086/377534 Borg, 2009, Prevalence of penicillin and erythromycin resistance among invasiveStreptococcus pneumoniae isolates reported by laboratories in the southern and eastern Mediterranean region, Clin Microbiol Infect, 15, 232, 10.1111/j.1469-0691.2008.02651.x Moore, 2008, Population snapshot of emergentStreptococcus pneumoniae serotype 19A in the United States, 2005, J Infect Dis, 197, 1016, 10.1086/528996 Ardanuy, 2009, Emergence of a multidrug‐resistant clone (ST320) among invasive serotype 19A pneumococci in Spain, J Antimicrob Chemother, 64, 507, 10.1093/jac/dkp210 Clinical and Laboratory Standards Institute, 2008 Peterson, 2006, Penicillins for treatment of pneumococcal pneumonia: does in vitro resistance really matter?, Clin Infect Dis, 42, 224, 10.1086/497594 File, 2005, Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community‐acquired pneumonia caused byStreptococcus pneumoniae, including penicillin‐resistant strains, Int J Antimicrob Agents, 25, 110, 10.1016/j.ijantimicag.2004.10.007 Weisblum, 1995, Erythromycin resistance by ribosome modification, Antimicrob Agents Chemother, 39, 577, 10.1128/AAC.39.3.577 Syrogiannopoulos, 2001, Identification of an erm(A) erythromycin resistance methylase gene inStreptococcus pneumoniae isolated in Greece, Antimicrob Agents Chemother, 45, 342, 10.1128/AAC.45.1.342-344.2001 Johnston, 1998, Prevalence and characterization of the mechanisms of macrolide, lincosamide, and streptogramin resistance in isolates ofStreptococcus pneumoniae, Antimicrob Agents Chemother, 42, 2425, 10.1128/AAC.42.9.2425 Farrell, 2003, Macrolide resistance by ribosomal mutation in clinical isolates ofStreptococcus pneumoniae from the PROTEKT 1999–2000 study, Antimicrob Agents Chemother, 47, 1777, 10.1128/AAC.47.6.1777-1783.2003 Lonks, 2002, Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin‐resistantStreptococcus pneumoniae, Clin Infect Dis, 35, 556, 10.1086/341978 Daneman, 2006, Macrolide resistance in bacteremic pneumococcal disease: implications for patient management, Clin Infect Dis, 43, 432, 10.1086/505871 Doern, 2006, Macrolide and ketolide resistance withStreptococcus pneumoniae, Med Clin North Am, 90, 1109, 10.1016/j.mcna.2006.07.010 Anderson, 2007, Comparison of the effects of macrolides, amoxicillin, ceftriaxone, doxycycline, tobramycin and fluoroquinolones, on the production of pneumolysin byStreptococcus pneumoniae in vitro, J Antimicrob Chemother, 60, 1155, 10.1093/jac/dkm338 Pan, 1996, Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets inStreptococcus pneumoniae, Antimicrob Agents Chemother, 40, 2321, 10.1128/AAC.40.10.2321 Blondeau, 2001, Mutant prevention concentrations of fluoroquinolones for clinical isolates ofStreptococcus pneumoniae, Antimicrob Agents Chemother, 45, 433, 10.1128/AAC.45.2.433-438.2001 de la Campa, 2009, Changes in fluoroquinolone‐resistantStreptococcus pneumoniae after 7‐valent conjugate vaccination, Spain, Emerg Infect Dis, 15, 905, 10.3201/eid1506.080684 Farrell, 2008, Non‐susceptibility trends and serotype distributions amongStreptococcus pneumoniae from community‐acquired respiratory tract infections and from bacteraemias in the UK and Ireland, 1999 to 2007, J Antimicrob Chemother, 62, ii87 Jansen, 2006, Longitudinal European surveillance study of antibiotic resistance ofHaemophilus influenzae, J Antimicrob Chemother, 58, 873, 10.1093/jac/dkl310 Peric, 2003, Effects of an efflux mechanism and ribosomal mutations on macrolide susceptibility ofHaemophilus influenzae clinical isolates, Antimicrob Agents Chemother, 47, 1017, 10.1128/AAC.47.3.1017-1022.2003 Morrissey, 2008, Non‐susceptibility trends amongHaemophilus influenzae and Moraxella catarrhalis from community‐acquired respiratory tract infections in the UK and Ireland, 1999–2007, J Antimicrob Chemother, 62, ii97 Kofteridis, 2008, Antimicrobial susceptibilities of 930Haemophilus influenzae clinical strains isolated from the island of Crete, Greece, Chemotherapy, 54, 492, 10.1159/000160183 Critchley, 2007, National and regional assessment of antimicrobial resistance among community‐acquired respiratory tract pathogens identified in a 2005–2006 U.S. Faropenem surveillance study, Antimicrob Agents Chemother, 51, 4382, 10.1128/AAC.00971-07 Waites, 2003, In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS‐284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas, Antimicrob Agents Chemother, 47, 161, 10.1128/AAC.47.1.161-165.2003 Waites, 2003, In vitro activities of ABT‐773 and other antimicrobials against human mycoplasmas, Antimicrob Agents Chemother, 47, 39, 10.1128/AAC.47.1.39-42.2003 Waites, 2004, Mycoplasma pneumoniae and its role as a human pathogen, Clin Microbiol Rev, 17, 697, 10.1128/CMR.17.4.697-728.2004 Matsuoka, 2004, Characterization and molecular analysis of macrolide‐resistantMycoplasma pneumoniae clinical isolates obtained in Japan, Antimicrob Agents Chemother, 48, 4624, 10.1128/AAC.48.12.4624-4630.2004 Morozumi, 2005, Emergence of macrolide‐resistantMycoplasma pneumoniae with a 23S rRNA gene mutation, Antimicrob Agents Chemother, 49, 2302, 10.1128/AAC.49.6.2302-2306.2005 Morozumi, 2008, Increased macrolide resistance ofMycoplasma pneumoniae in pediatric patients with community‐acquired pneumonia, Antimicrob Agents Chemother, 52, 348, 10.1128/AAC.00779-07 Dumke, 2010, Occurrence of macrolide‐resistantMycoplasma pneumoniae strains in Germany, Clin Microbiol Infect, 16, 613, 10.1111/j.1469-0691.2009.02968.x Peuchant, 2009, Increased macrolide resistance ofMycoplasma pneumoniae in France directly detected in clinical specimens by real‐time PCR and melting curve analysis, J Antimicrob Chemother, 64, 52, 10.1093/jac/dkp160 Stralin, 2006, Staphylococcus aureus in community‐acquired pneumonia, Chest, 130, 623, 10.1378/chest.130.2.623-a Morens, 2008, Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness, J Infect Dis, 198, 962, 10.1086/591708 Nathwani, 2008, Guidelines for UK practice for the diagnosis and management of methicillin‐resistantStaphylococcus aureus (MRSA) infections presenting in the community, J Antimicrob Chemother, 61, 976, 10.1093/jac/dkn096 Drusano, 2004, Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia, J Infect Dis, 189, 1590, 10.1086/383320 Hutschala, 2005, In vivo measurement of levofloxacin penetration into lung tissue after cardiac surgery, Antimicrob Agents Chemother, 49, 5107, 10.1128/AAC.49.12.5107-5111.2005 Conte, 2007, Intrapulmonary pharmacodynamics of high‐dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease, Int J Antimicrob Agents, 30, 422, 10.1016/j.ijantimicag.2007.05.023 Bhavnani, 2008, Pharmacokinetics‐pharmacodynamics of quinolones againstStreptococcus pneumoniae in patients with community‐acquired pneumonia, Diagn Microbiol Infect Dis, 62, 99, 10.1016/j.diagmicrobio.2008.04.008 Aspromonte, 2006, Early diagnosis of congestive heart failure: clinical utility of B‐type natriuretic peptide testing associated with Doppler echocardiography, J Cardiovasc Med (Hagerstown), 7, 406, 10.2459/01.JCM.0000228690.40452.d3 Mikkelsen, 2006, Neurohormonal activation and diagnostic value of cardiac peptides in patients with suspected mild heart failure, Int J Cardiol, 110, 324, 10.1016/j.ijcard.2005.08.003 Fuat, 2006, The diagnostic accuracy and utility of a B‐type natriuretic peptide test in a community population of patients with suspected heart failure, Br J Gen Pract, 56, 327 Van Schayck, 2002, Detecting patients at a high risk of developing chronic obstructive pulmonary disease in general practice: cross sectional case finding study, BMJ, 324, 1370, 10.1136/bmj.324.7350.1370 Broekhuizen, 2009, The diagnostic value of history and physical examination for COPD in suspected or known cases: a systematic review, Fam Pract, 26, 260, 10.1093/fampra/cmp026 Hopstaken, 2003, Contributions of symptoms, signs, erythrocyte sedimentation rate, and C‐reactive protein to a diagnosis of pneumonia in acute lower respiratory tract infection, Br J Gen Pract, 53, 358 Graffelman, 2007, Can history and exam alone reliably predict pneumonia?, J Fam Pract, 56, 465 Flanders, 2004, Performance of a bedside C‐reactive protein test in the diagnosis of community‐acquired pneumonia in adults with acute cough, Am J Med, 116, 529, 10.1016/j.amjmed.2003.11.023 Holm, 2007, Procalcitonin versus C‐reactive protein for predicting pneumonia in adults with lower respiratory tract infection in primary care, Br J Gen Pract, 57, 555 van der, 2005, Diagnostic value of C reactive protein in infections of the lower respiratory tract: systematic review, BMJ, 331, 26, 10.1136/bmj.38483.478183.EB Falk, 2009, C‐reactive protein and community‐acquired pneumonia in ambulatory care: systematic review of diagnostic accuracy studies, Fam Pract, 26, 10, 10.1093/fampra/cmn095 Graffelman, 2004, A diagnostic rule for the aetiology of lower respiratory tract infections as guidance for antimicrobial treatment, Br J Gen Pract, 54, 20 Bauer, 2006, CRB‐65 predicts death from community‐acquired pneumonia, J Intern Med, 260, 93, 10.1111/j.1365-2796.2006.01657.x Bont, 2007, A prediction rule for elderly primary‐care patients with lower respiratory tract infections, Eur Respir J, 29, 969, 10.1183/09031936.00129706 Bont, 2008, Predicting death in elderly patients with community‐acquired pneumonia: a prospective validation study reevaluating the CRB‐65 severity assessment tool, Arch Intern Med, 168, 1465, 10.1001/archinte.168.13.1465 Bont, 2008 Hak, 2005, Prognostic factors for serious morbidity and mortality from community‐acquired lower respiratory tract infections among the elderly in primary care, Fam Pract, 22, 375, 10.1093/fampra/cmi020 Seppa, 2001, Severity assessment of lower respiratory tract infection in elderly patients in primary care, Arch Intern Med, 161, 2709, 10.1001/archinte.161.22.2709 Smith, 2010 Smucny, 2010 Ponsioen, 2005, Efficacy of fluticasone on cough: a randomised controlled trial, Eur Respir J, 25, 147, 10.1183/09031936.04.00053604 Smith, 2010 Little, 2005, Information leaflet and antibiotic prescribing strategies for acute lower respiratory tract infection: a randomized controlled trial, JAMA, 293, 3029, 10.1001/jama.293.24.3029 Ram, 2006, Antibiotics for exacerbations of chronic obstructive pulmonary disease, Cochrane Database Syst Rev, 2, 10.1002/14651858.CD004403.pub2 Bjerre, 2004, Antibiotics for community acquired pneumonia in adult outpatients, Cochrane Database Syst Rev, 2, 10.1002/14651858.CD002109.pub2 Mills, 2005, Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non‐severe community acquired pneumonia: meta‐analysis, BMJ, 330, 456, 10.1136/bmj.38334.591586.82 Cooper, 2003, Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta‐analyses of randomised controlled trials, BMJ, 326, 1235, 10.1136/bmj.326.7401.1235 Jefferson, 2006, Antivirals for influenza in healthy adults: systematic review, Lancet, 367, 303, 10.1016/S0140-6736(06)67970-1 Lim, 2003, Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study, Thorax, 58, 377, 10.1136/thorax.58.5.377 Ewig, 2004, Validation of predictive rules and indices of severity for community acquired pneumonia, Thorax, 59, 421, 10.1136/thx.2003.008110 Ewig, 2009, New perspectives on community‐acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality, Thorax, 64, 1062, 10.1136/thx.2008.109785 Aujesky, 2009, Reasons why emergency department providers do not rely on the pneumonia severity index to determine the initial site of treatment for patients with pneumonia, Clin Infect Dis, 49, e100, 10.1086/644741 Capelastegui, 2006, Validation of a predictive rule for the management of community‐acquired pneumonia, Eur Respir J, 27, 151, 10.1183/09031936.06.00062505 Buising, 2006, A prospective comparison of severity scores for identifying patients with severe community acquired pneumonia: reconsidering what is meant by severe pneumonia, Thorax, 61, 419, 10.1136/thx.2005.051326 Man, 2007, Prospective comparison of three predictive rules for assessing severity of community‐acquired pneumonia in Hong Kong, Thorax, 62, 348, 10.1136/thx.2006.069740 Myint, 2006, Age Ageing, 35, 286, 10.1093/ageing/afj081 Barlow, 2007, The CURB65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community‐acquired pneumonia, Thorax, 62, 253, 10.1136/thx.2006.067371 Chalmers, 2008, Systolic blood pressure is superior to other haemodynamic predictors of outcome in community acquired pneumonia, Thorax, 63, 698, 10.1136/thx.2008.095562 Labarere, 2006, Factors associated with the hospitalization of low‐risk patients with community‐acquired pneumonia in a cluster‐randomized trial, J Gen Intern Med, 21, 745, 10.1111/j.1525-1497.2006.00510.x Marrie, 2007, Admission is not always necessary for patients with community‐acquired pneumonia in risk classes IV and V diagnosed in the emergency room, Can Respir J, 14, 212, 10.1155/2007/451417 Seymann, 2008, Clinical judgment versus the Pneumonia Severity Index in making the admission decision, J Emerg Med, 34, 261, 10.1016/j.jemermed.2007.05.050 Loeb, 2006, Effect of a clinical pathway to reduce hospitalizations in nursing home residents with pneumonia: a randomized controlled trial, JAMA, 295, 2503, 10.1001/jama.295.21.2503 Hirakata, 2008, Comparison of usefulness of plasma procalcitonin and C‐reactive protein measurements for estimation of severity in adults with community‐acquired pneumonia, Diagn Microbiol Infect Dis, 61, 170, 10.1016/j.diagmicrobio.2008.01.014 Hohenthal, 2009, Utility of C‐reactive protein in assessing the disease severity and complications of community‐acquired pneumonia, Clin Microbiol Infect, 15, 1026, 10.1111/j.1469-0691.2009.02856.x Menendez, 2009, Biomarkers improve mortality prediction by prognostic scales in community‐acquired pneumonia, Thorax, 64, 587, 10.1136/thx.2008.105312 Thiem, 2009, C‐reactive protein, severity of pneumonia and mortality in elderly, hospitalised patients with community‐acquired pneumonia, Age Ageing, 38, 693, 10.1093/ageing/afp164 Okimoto, 2009, Procalcitonin and severity of community‐acquired pneumonia, J Infect Chemother, 15, 426, 10.1007/s10156-009-0722-8 Kruger, 2007, Pro‐atrial natriuretic peptide and pro‐vasopressin to predict severity and prognosis in community‐acquired pneumonia: results from the German competence network CAPNETZ, Intensive Care Med, 33, 2069, 10.1007/s00134-007-0895-5 Chalmers, 2009, Admission D‐dimer can identify low‐risk patients with community‐acquired pneumonia, Ann Emerg Med, 53, 633, 10.1016/j.annemergmed.2008.12.022 Kruger, 2009, C‐terminal provasopressin (copeptin) in patients with community‐acquired pneumonia – influence of antibiotic pre‐treatment: results from the German competence network CAPNETZ, J Antimicrob Chemother, 64, 159, 10.1093/jac/dkp148 Christ‐Crain, 2008, Use of B‐type natriuretic peptide in the risk stratification of community‐acquired pneumonia, J Intern Med, 264, 166, 10.1111/j.1365-2796.2008.01934.x Prat, 2007, Midregional pro‐atrial natriuretic peptide as a prognostic marker in pneumonia, J Infect, 55, 400, 10.1016/j.jinf.2007.07.018 Christ‐Crain, 2006, Pro‐adrenomedullin to predict severity and outcome in community‐acquired pneumonia [ISRCTN04176397], Crit Care, 10, R96, 10.1186/cc4955 Huang, 2009, Midregional proadrenomedullin as a prognostic tool in community‐acquired pneumonia, Chest, 136, 823, 10.1378/chest.08-1981 Tejera, 2007, Prognosis of community acquired pneumonia (CAP): value of triggering receptor expressed on myeloid cells‐1 (TREM‐1) and other mediators of the inflammatory response, Cytokine, 38, 117, 10.1016/j.cyto.2007.05.002 Christ‐Crain, 2007, Free and total cortisol levels as predictors of severity and outcome in community‐acquired pneumonia, Am J Respir Crit Care Med, 176, 913, 10.1164/rccm.200702-307OC Salluh, 2008, Adrenal response in severe community‐acquired pneumonia: impact on outcomes and disease severity, Chest, 134, 947, 10.1378/chest.08-1382 Kruger, 2008, Procalcitonin predicts patients at low risk of death from community‐acquired pneumonia across all CRB‐65 classes, Eur Respir J, 31, 349, 10.1183/09031936.00054507 Huang, 2008, Risk prediction with procalcitonin and clinical rules in community‐acquired pneumonia, Ann Emerg Med, 52, 48, 10.1016/j.annemergmed.2008.01.003 Phua, 2009, Validation and clinical implications of the IDSA/ATS minor criteria for severe community‐acquired pneumonia, Thorax, 64, 598, 10.1136/thx.2009.113795 Charles, 2008, SMART‐COP: a tool for predicting the need for intensive respiratory or vasopressor support in community‐acquired pneumonia, Clin Infect Dis, 47, 375, 10.1086/589754 Chalmers, 2008, Predicting the need for mechanical ventilation and/or inotropic support for young adults admitted to the hospital with community‐acquired pneumonia, Clin Infect Dis, 47, 1571, 10.1086/593195 Brown, 2009, Validation of the Infectious Disease Society of America/American Thoracic Society 2007 guidelines for severe community‐acquired pneumonia, Crit Care Med, 37, 3010, 10.1097/CCM.0b013e3181b030d9 Marrie, 2007, Community‐acquired pneumonia requiring admission to an intensive care unit: a descriptive study, Medicine (Baltimore), 86, 103, 10.1097/MD.0b013e3180421c16 Riley, 2004, Validation of the 2001 American Thoracic Society criteria for severe community‐acquired pneumonia, Crit Care Med, 32, 2398, 10.1097/01.CCM.0000147443.38234.D2 Renaud, 2009, Association between timing of intensive care unit admission and outcomes for emergency department patients with community‐acquired pneumonia, Crit Care Med, 37, 2867, 10.1097/CCM.0b013e3181b02dbb Bruns, 2008, Usefulness of consecutive C‐reactive protein measurements in follow‐up of severe community‐acquired pneumonia, Eur Respir J, 32, 726, 10.1183/09031936.00003608 Wu, 2007, Early evolution of arterial oxygenation in severe community‐acquired pneumonia: a prospective observational study, J Crit Care, 22, 129, 10.1016/j.jcrc.2006.06.009 Marrie, 1989, Community‐acquired pneumonia requiring hospitalization: 5‐year prospective study, Rev Infect Dis, 11, 586, 10.1093/clinids/11.4.586 Gleckman, 1988, Sputum gram stain assessment in community‐acquired bacteremic pneumonia, J Clin Microbiol, 26, 846, 10.1128/JCM.26.5.846-849.1988 Benenson, 2007, Selective use of blood cultures in emergency department pneumonia patients, J Emerg Med, 33, 1, 10.1016/j.jemermed.2006.12.034 Afshar, 2009, Blood cultures for community‐acquired pneumonia: are they worthy of two quality measures? A systematic review, J Hosp Med, 4, 112, 10.1002/jhm.382 Bradley, 2005, Staphylococcus aureus pneumonia: emergence of MRSA in the community, Semin Respir Crit Care Med, 26, 643, 10.1055/s-2005-925528 El Solh, 2007, Diagnostic yield of quantitative endotracheal aspirates in patients with severe nursing home‐acquired pneumonia, Crit Care, 11, R57, 10.1186/cc5917 Lagerstrom, 2004, Sputum specimens can be obtained from patients with community‐acquired pneumonia in primary care, Scand J Prim Health Care, 22, 83, 10.1080/02813430410006468 Garcia‐Vazquez, 2004, Assessment of the usefulness of sputum culture for diagnosis of community‐acquired pneumonia using the PORT predictive scoring system, Arch Intern Med, 164, 1807, 10.1001/archinte.164.16.1807 van der Eerden, 2005, Value of intensive diagnostic microbiological investigation in low‐ and high‐risk patients with community‐acquired pneumonia, Eur J Clin Microbiol Infect Dis, 24, 241, 10.1007/s10096-005-1316-8 Musher, 2004, Diagnostic value of microscopic examination of Gram‐stained sputum and sputum cultures in patients with bacteremic pneumococcal pneumonia, Clin Infect Dis, 39, 165, 10.1086/421497 Signori, 2008, Sputum examination in the clinical management of community‐acquired pneumonia, J Bras Pneumol, 34, 152, 10.1590/S1806-37132008000300005 Anevlavis, 2009, A prospective study of the diagnostic utility of sputum Gram stain in pneumonia, J Infect, 59, 83, 10.1016/j.jinf.2009.05.011 Uffredi, 2003, Significance of Aspergillus fumigatus isolation from respiratory specimens of nongranulocytopenic patients, Eur J Clin Microbiol Infect Dis, 22, 457, 10.1007/s10096-003-0970-y Ortega, 2005, Utility of a pneumonia severity index in the optimization of the diagnostic and therapeutic effort for community‐acquired pneumonia, Scand J Infect Dis, 37, 657, 10.1080/00365540510027174 Gutierrez, 2003, Evaluation of the immunochromatographic Binax NOW assay for detection ofStreptococcus pneumoniae urinary antigen in a prospective study of community‐acquired pneumonia in Spain, Clin Infect Dis, 36, 286, 10.1086/345852 Smith, 2003, Susceptibility testing ofPseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis, Chest, 123, 1495, 10.1378/chest.123.5.1495 Marcos, 2003, Rapid urinary antigen test for diagnosis of pneumococcal community‐acquired pneumonia in adults, Eur Respir J, 21, 209, 10.1183/09031936.03.00058802 Roson, 2004, Contribution of a urinary antigen assay (Binax NOW) to the early diagnosis of pneumococcal pneumonia, Clin Infect Dis, 38, 222, 10.1086/380639 Ishida, 2004, A 3‐year prospective study of a urinary antigen‐detection test forStreptococcus pneumoniae in community‐acquired pneumonia: utility and clinical impact on the reported etiology, J Infect Chemother, 10, 359, 10.1007/s10156-004-0351-1 Stralin, 2004, Comparison of two urinary antigen tests for establishment of pneumococcal etiology of adult community‐acquired pneumonia, J Clin Microbiol, 42, 3620, 10.1128/JCM.42.8.3620-3625.2004 Andreo, 2006, Usefulness of pneumococcal antigen detection in pleural fluid samples by immunochromatographic assay for diagnosis of pneumococcal pneumonia, Clin Microbiol Infect, 12, 682, 10.1111/j.1469-0691.2006.01484.x Ercis, 2006, Validation of urinary antigen test forStreptococcus pneumoniae in patients with pneumococcal pneumonia, Jpn J Infect Dis, 59, 388 Genne, 2006, Analysis of factors that contribute to treatment failure in patients with community‐acquired pneumonia, Eur J Clin Microbiol Infect Dis, 25, 159, 10.1007/s10096-006-0113-3 Lasocki, 2006, Evaluation of the Binax NOWStreptococcus pneumoniae urinary antigen assay in intensive care patients hospitalized for pneumonia, Intensive Care Med, 32, 1766, 10.1007/s00134-006-0329-9 Leeming, 2005, Diagnosis of invasive pneumococcal infection by serotype‐specific urinary antigen detection, J Clin Microbiol, 43, 4972, 10.1128/JCM.43.10.4972-4976.2005 Kobashi, 2007, Evaluating the use of aStreptococcus pneumoniae urinary antigen detection kit for the management of community‐acquired pneumonia in Japan, Respiration, 74, 387, 10.1159/000092547 Oka, 2009, The efficacy of high‐dose penicillin for community‐acquired pneumonia diagnosed by pneumococcal urine antigen test, J Infect Chemother, 15, 108, 10.1007/s10156-009-0672-1 Smith, 2009, Diagnosis ofStreptococcus pneumoniae infections in adults with bacteremia and community‐acquired pneumonia: clinical comparison of pneumococcal PCR and urinary antigen detection, J Clin Microbiol, 47, 1046, 10.1128/JCM.01480-08 Andreo, 2009, Persistence ofStreptococcus pneumoniae urinary antigen excretion after pneumococcal pneumonia, Eur J Clin Microbiol Infect Dis, 28, 197, 10.1007/s10096-008-0606-3 Korsgaard, 2005, Antibiotic treatment and the diagnosis ofStreptococcus pneumoniae in lower respiratory tract infections in adults, Int J Infect Dis, 9, 274, 10.1016/j.ijid.2004.07.013 Dominguez, 2006, Rapid detection of pneumococcal antigen in serum samples for diagnosing pneumococcal pneumonia, J Infect, 53, 21, 10.1016/j.jinf.2005.09.008 Porcel, 2007, Contribution of a pleural antigen assay (Binax NOW) to the diagnosis of pneumococcal pneumonia, Chest, 131, 1442, 10.1378/chest.06-1884 Dirven, 2005, Comparison of three Legionella urinary antigen assays during an outbreak of legionellosis in Belgium, J Med Microbiol, 54, 1213, 10.1099/jmm.0.45909-0 Guerrero, 2004, Comparison of diagnostic sensitivities of three assays (Bartels enzyme immunoassay [EIA], Biotest EIA, and Binax NOW immunochromatographic test) for detection of Legionella pneumophila serogroup 1 antigen in urine, J Clin Microbiol, 42, 467, 10.1128/JCM.42.1.467-468.2004 Olsen, 2009, Comparison of the sensitivity of the Legionella urinary antigen EIA kits from Binax and Biotest with urine from patients with infections caused by less common serogroups and subgroups of Legionella, Eur J Clin Microbiol Infect Dis, 28, 817, 10.1007/s10096-008-0697-x Blanco, 2008, Detection of Legionella antigen in nonconcentrated and concentrated urine samples by a new immunochromatographic assay, Eur J Clin Microbiol Infect Dis, 27, 1249, 10.1007/s10096-008-0559-6 Diederen, 2009, Evaluation of the Oxoid Xpect Legionella test kit for detection of Legionella pneumophila serogroup 1 antigen in urine, J Clin Microbiol, 47, 2272, 10.1128/JCM.00397-09 Alvarez, 2009, Impact of the Legionella urinary antigen test on epidemiological trends in community outbreaks of legionellosis in Catalonia, Spain, 1990–2004, Int J Infect Dis, 13, e365, 10.1016/j.ijid.2009.01.004 Blazquez, 2005, Sensitivity of urinary antigen test in relation to clinical severity in a large outbreak of Legionella pneumonia in Spain, Eur J Clin Microbiol Infect Dis, 24, 488, 10.1007/s10096-005-1361-3 von, 2008, Community‐acquired Legionella pneumonia: new insights from the German competence network for community acquired pneumonia, Clin Infect Dis, 46, 1356, 10.1086/586741 Steininger, 2009, Near‐patient assays for diagnosis of influenza virus infection in adult patients, Clin Microbiol Infect, 15, 267, 10.1111/j.1469-0691.2008.02674.x Falsey, 2007, Respiratory syncytial virus infection in adults, Semin Respir Crit Care Med, 28, 171, 10.1055/s-2007-976489 Beersma, 2005, Evaluation of 12 commercial tests and the complement fixation test forMycoplasma pneumoniae‐specific immunoglobulin G (IgG) and IgM antibodies, with PCR used as the “gold standard”, J Clin Microbiol, 43, 2277, 10.1128/JCM.43.5.2277-2285.2005 Talkington, 2004, Analysis of eight commercial enzyme immunoassay tests for detection of antibodies toMycoplasma pneumoniae in human serum, Clin Diagn Lab Immunol, 11, 862, 10.1128/CDLI.11.5.862-867.2004 Nir‐Paz, 2006, Evaluation of eight commercial tests forMycoplasma pneumoniae antibodies in the absence of acute infection, Clin Microbiol Infect, 12, 685, 10.1111/j.1469-0691.2006.01469.x Templeton, 2003, Comparison and evaluation of real‐time PCR, real‐time nucleic acid sequence‐based amplification, conventional PCR, and serology for diagnosis ofMycoplasma pneumoniae, J Clin Microbiol, 41, 4366, 10.1128/JCM.41.9.4366-4371.2003 Martinez, 2008, Detection ofMycoplasma pneumoniae in adult community‐acquired pneumonia by PCR and serology, J Med Microbiol, 57, 1491, 10.1099/jmm.0.2008/003814-0 von, 2009, Mycoplasma pneumoniae pneumonia revisited within the German Competence Network for Community‐acquired pneumonia (CAPNETZ), BMC Infect Dis, 9, 62, 10.1186/1471-2334-9-62 Hvidsten, 2009, Chlamydophila pneumoniae diagnostics: importance of methodology in relation to timing of sampling, Clin Microbiol Infect, 15, 42, 10.1111/j.1469-0691.2008.02075.x Elverdal, 2008, Comparison and evaluation of four commercial kits relative to an in‐house immunofluorescence test for detection of antibodies against Legionella pneumophila, Eur J Clin Microbiol Infect Dis, 27, 149, 10.1007/s10096-007-0410-5 Johansson, 2008, Quantitative detection ofStreptococcus pneumoniae from sputum samples with real‐time quantitative polymerase chain reaction for etiologic diagnosis of community‐acquired pneumonia, Diagn Microbiol Infect Dis, 60, 255, 10.1016/j.diagmicrobio.2007.10.011 Abdeldaim, 2010, Usefulness of real‐time PCR for lytA, ply, and Spn9802 on plasma samples for the diagnosis of pneumococcal pneumonia, Clin Microbiol Infect, 16, 1135, 10.1111/j.1469-0691.2009.03069.x Peters, 2009, Streptococcus pneumoniae DNA load in blood as a marker of infection in patients with community‐acquired pneumonia, J Clin Microbiol, 47, 3308, 10.1128/JCM.01071-09 Rello, 2009, Severity of pneumococcal pneumonia associated with genomic bacterial load, Chest, 136, 832, 10.1378/chest.09-0258 Abdeldaim, 2009, Detection ofHaemophilus influenzae in respiratory secretions from pneumonia patients by quantitative real‐time polymerase chain reaction, Diagn Microbiol Infect Dis, 64, 366, 10.1016/j.diagmicrobio.2009.03.030 Maurin, 2010, Quantitative real‐time PCR tests for diagnostic and prognostic purposes in cases of legionellosis, Clin Microbiol Infect, 16, 379, 10.1111/j.1469-0691.2009.02812.x Raty, 2005, Sample type is crucial to the diagnosis ofMycoplasma pneumoniae pneumonia by PCR, J Med Microbiol, 54, 287, 10.1099/jmm.0.45888-0 Diederen, 2008, Utility of real‐time PCR for diagnosis of Legionnaires’ disease in routine clinical practice, J Clin Microbiol, 46, 671, 10.1128/JCM.01196-07 Nilsson, 2008, Polymerase chain reaction is superior to serology for the diagnosis of acuteMycoplasma pneumoniae infection and reveals a high rate of persistent infection, BMC Microbiol, 8, 93, 10.1186/1471-2180-8-93 Thurman, 2009, Comparison of laboratory diagnostic procedures for detection ofMycoplasma pneumoniae in community outbreaks, Clin Infect Dis, 48, 1244, 10.1086/597775 Andre, 2008, Comparison of serological and real‐time PCR assays to diagnose Bordetella pertussis infection in 2007, J Clin Microbiol, 46, 1672, 10.1128/JCM.02187-07 Sotir, 2007, Evaluation of polymerase chain reaction and culture for diagnosis of pertussis in the control of a county‐wide outbreak focused among adolescents and adults, Clin Infect Dis, 44, 1216, 10.1086/513432 Mahony, 2007, Development of a respiratory virus panel test for detection of twenty human respiratory viruses by use of multiplex PCR and a fluid microbead‐based assay, J Clin Microbiol, 45, 2965, 10.1128/JCM.02436-06 van de Pol, 2007, Increased detection of respiratory syncytial virus, influenza viruses, parainfluenza viruses, and adenoviruses with real‐time PCR in samples from patients with respiratory symptoms, J Clin Microbiol, 45, 2260, 10.1128/JCM.00848-07 Ginocchio, 2009, Evaluation of multiple test methods for the detection of the novel 2009 influenza A (H1N1) during the New York City outbreak, J Clin Virol, 45, 191, 10.1016/j.jcv.2009.06.005 Caram, 2009, Respiratory syncytial virus outbreak in a long‐term care facility detected using reverse transcriptase polymerase chain reaction: an argument for real‐time detection methods, J Am Geriatr Soc, 57, 482, 10.1111/j.1532-5415.2008.02153.x Berjohn, 2008, Treatment and outcomes for patients with bacteremic pneumococcal pneumonia, Medicine (Baltimore), 87, 160, 10.1097/MD.0b013e318178923a Cheng, 2009, Delayed administration of antibiotics and mortality in patients with community‐acquired pneumonia 89, Ann Emerg Med, 53, 618, 10.1016/j.annemergmed.2008.07.017 Fee, 2007, Identification of 90% of patients ultimately diagnosed with community‐acquired pneumonia within four hours of emergency department arrival may not be feasible, Ann Emerg Med, 49, 553, 10.1016/j.annemergmed.2006.11.008 Friedberg, 2009, Reporting hospitals’ antibiotic timing in pneumonia: adverse consequences for patients?, Am J Manag Care, 15, 137 Kanwar, 2007, Misdiagnosis of community‐acquired pneumonia and inappropriate utilization of antibiotics: side effects of the 4‐h antibiotic administration rule, Chest, 131, 1865, 10.1378/chest.07-0164 Pines, 2009, The measurement of time to first antibiotic dose for pneumonia in the emergency department: a white paper and position statement prepared for the American Academy of Emergency Medicine, J Emerg Med, 37, 335, 10.1016/j.jemermed.2009.06.127 Bruns, 2009, Time for first antibiotic dose is not predictive for the early clinical failure of moderate‐severe community‐acquired pneumonia, Eur J Clin Microbiol Infect Dis, 28, 913, 10.1007/s10096-009-0724-6 Iannini, 2007, A case series of macrolide treatment failures in community acquired pneumonia, J Chemother, 19, 536, 10.1179/joc.2007.19.5.536 Rzeszutek, 2004, A review of clinical failures associated with macrolide‐resistantStreptococcus pneumoniae, Int J Antimicrob Agents, 24, 95, 10.1016/j.ijantimicag.2004.03.008 Lodise, 2007, Comparison of beta‐lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community‐acquired pneumonia, Antimicrob Agents Chemother, 51, 3977, 10.1128/AAC.00006-07 Metersky, 2007, Antibiotics for bacteremic pneumonia: Improved outcomes with macrolides but not fluoroquinolones, Chest, 131, 466, 10.1378/chest.06-1426 Tessmer, 2009, Impact of intravenous {beta}‐lactam/macrolide versus {beta}‐lactam monotherapy on mortality in hospitalized patients with community‐acquired pneumonia, J Antimicrob Chemother, 63, 1025, 10.1093/jac/dkp088 Paul, 2007, The need for macrolides in hospitalised community‐acquired pneumonia: propensity analysis, Eur Respir J, 30, 525, 10.1183/09031936.00031007 File, 2007, The development of pharmacokinetically enhanced amoxicillin/clavulanate for the management of respiratory tract infections in adults, Int J Antimicrob Agents, 30, S131, 10.1016/j.ijantimicag.2007.07.038 Petitpretz, 2002, The efficacy and safety of oral pharmacokinetically enhanced amoxycillin‐clavulanate 2000/125 mg, twice daily, versus oral amoxycillin‐clavulanate 1000/125 mg, three times daily, for the treatment of bacterial community‐acquired pneumonia in adults, Int J Antimicrob Agents, 20, 119, 10.1016/S0924-8579(02)00126-7 Siquier, 2006, Efficacy and safety of twice‐daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community‐acquired pneumonia in a country with a high prevalence of penicillin‐resistantStreptococcus pneumoniae, J Antimicrob Chemother, 57, 536, 10.1093/jac/dki480 Dartois, 2008, Tigecycline versus levofloxacin for the treatment of community‐acquired pneumonia: European experience, J Chemother, 20, 28, 10.1179/joc.2008.20.Supplement-1.28 Lin, 2007, An open‐label, randomized comparison of levofloxacin and amoxicillin/clavulanate plus clarithromycin for the treatment of hospitalized patients with community‐acquired pneumonia, Chang Gung Med J, 30, 321 Portier, 2005, Moxifloxacin monotherapy compared to amoxicillin‐clavulanate plus roxithromycin for nonsevere community‐acquired pneumonia in adults with risk factors, Eur J Clin Microbiol Infect Dis, 24, 367, 10.1007/s10096-005-1347-1 Querol‐Ribelles, 2005, Levofloxacin versus ceftriaxone plus clarithromycin in the treatment of adults with community‐acquired pneumonia requiring hospitalization, Int J Antimicrob Agents, 25, 75, 10.1016/j.ijantimicag.2004.07.013 Salkind, 2002, Fluoroquinolone treatment of community‐acquired pneumonia: a meta‐analysis, Ann Pharmacother, 36, 1938, 10.1345/aph.1C167 Schein, 2008, A comparison of levofloxacin and moxifloxacin use in hospitalized community‐acquired pneumonia (CAP) patients in the US: focus on length of stay, Curr Med Res Opin, 24, 895, 10.1185/030079908X273408 Tanaseanu, 2008, Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community‐acquired pneumonia 509, Diagn Microbiol Infect Dis, 61, 329, 10.1016/j.diagmicrobio.2008.04.009 Tanaseanu, 2009, Efficacy and safety of tigecycline versus levofloxacin for community‐acquired pneumonia, BMC Pulm Med, 9, 44, 10.1186/1471-2466-9-44 Torres, 2003, Effectiveness of oral moxifloxacin in standard first‐line therapy in community‐acquired pneumonia, Eur Respir J, 21, 135, 10.1183/09031936.03.00045202 Vardakas, 2008, Respiratory fluoroquinolones for the treatment of community‐acquired pneumonia: a meta‐analysis of randomized controlled trials, CMAJ, 179, 1269, 10.1503/cmaj.080358 Van, 2009, Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes, Drug Saf, 32, 359, 10.2165/00002018-200932050-00001 Bergallo, 2009, Safety and efficacy of intravenous tigecycline in treatment of community‐acquired pneumonia: results from a double‐blind randomized phase 3 comparison study with levofloxacin, Diagn Microbiol Infect Dis, 63, 52, 10.1016/j.diagmicrobio.2008.09.001 Ortiz‐Ruiz, 2004, Ertapenem versus ceftriaxone for the treatment of community‐acquired pneumonia in adults: combined analysis of two multicentre randomized, double‐blind studies, J Antimicrob Chemother, 53, ii59 Vetter, 2002, A prospective, randomized, double‐blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community‐acquired pneumonia, Clin Ther, 24, 1770, 10.1016/S0149-2918(02)80078-9 Yakovlev, 2006, Ertapenem versus cefepime for initial empirical treatment of pneumonia acquired in skilled‐care facilities or in hospitals outside the intensive care unit, Eur J Clin Microbiol Infect Dis, 25, 633, 10.1007/s10096-006-0193-0 Kothe, 2008, Outcome of community‐acquired pneumonia: influence of age, residence status and antimicrobial treatment, Eur Respir J, 32, 139, 10.1183/09031936.00092507 Murcia, 2009, Clinical response to ertapenem in severe community‐acquired pneumonia: a retrospective series in an elderly population, Clin Microbiol Infect, 15, 1046, 10.1111/j.1469-0691.2009.02843.x Paladino, 2007, Once‐daily cefepime versus ceftriaxone for nursing home‐acquired pneumonia, J Am Geriatr Soc, 55, 651, 10.1111/j.1532-5415.2007.01152.x von, 2010, Community‐acquired pneumonia through Enterobacteriaceae andPseudomonas aeruginosa: Diagnosis, incidence and predictors, Eur Respir J, 35, 598, 10.1183/09031936.00091809 Frei, 2003, Impact of atypical coverage for patients with community‐acquired pneumonia managed on the medical ward: results from the United States Community‐Acquired Pneumonia Project, Pharmacotherapy, 23, 1167, 10.1592/phco.23.10.1167.32764 Lui, 2009, Role of ‘atypical pathogens’ among adult hospitalized patients with community‐acquired pneumonia, Respirology, 14, 1098, 10.1111/j.1440-1843.2009.01637.x Shefet, 2005, Empiric antibiotic coverage of atypical pathogens for community acquired pneumonia in hospitalized adults, Cochrane Database Syst Rev, 2, 10.1002/14651858.CD004418.pub2 Garcia, 2005, Lower mortality among patients with community‐acquired pneumonia treated with a macrolide plus a beta‐lactam agent versus a beta‐lactam agent alone, Eur J Clin Microbiol Infect Dis, 24, 190, 10.1007/s10096-005-1295-9 Martinez, 2004, Monotherapy versus dual therapy for community‐acquired pneumonia in hospitalized patients, Clin Infect Dis, 38, S328, 10.1086/382689 Weiss, 2004, Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremicStreptococcus pneumoniae pneumonia in adults, Can Respir J, 11, 589, 10.1155/2004/461392 Alvarez, 2004, Clinical experience with levofloxacin in the treatment of pneumonia in ICU patients, J Chemother, 16, 15, 10.1080/1120009X.2004.11782368 Erard, 2004, Full‐course oral levofloxacin for treatment of hospitalized patients with community‐acquired pneumonia, Eur J Clin Microbiol Infect Dis, 23, 82, 10.1007/s10096-003-1060-x Katz, 2004, Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community‐acquired pneumonia in patients requiring initial i.v. therapy, J Emerg Med, 27, 395, 10.1016/j.jemermed.2004.02.023 Lode, 2003, Sequential IV/PO moxifloxacin treatment of patients with severe community‐acquired pneumonia, Respir Med, 97, 1134, 10.1016/S0954-6111(03)00166-5 Rodriguez, 2007, Combination antibiotic therapy improves survival in patients with community‐acquired pneumonia and shock, Crit Care Med, 35, 1493, 10.1097/01.CCM.0000266755.75844.05 Torres, 2008, Moxifloxacin monotherapy is effective in hospitalized patients with community‐acquired pneumonia: the MOTIV study – a randomized clinical trial, Clin Infect Dis, 46, 1499, 10.1086/587519 Wasserfallen, 2004, Cost‐effectiveness of full‐course oral levofloxacin in severe community‐acquired pneumonia, Eur Respir J, 24, 644, 10.1183/09031936.04.00143303 Romanelli, 2002, Carbapenems in the treatment of severe community‐acquired pneumonia in hospitalized elderly patients: a comparative study against standard therapy, J Chemother, 14, 609, 10.1179/joc.2002.14.6.609 Aspa, 2004, Drug‐resistant pneumococcal pneumonia: clinical relevance and related factors, Clin Infect Dis, 38, 787, 10.1086/381886 Bonnard, 2005, Community‐acquired bacteraemic pneumococcal pneumonia in adults: effect of diminished penicillin susceptibility on clinical outcome, J Infect, 51, 69, 10.1016/j.jinf.2004.08.016 Falco, 2004, Influence of penicillin resistance on outcome in adult patients with invasive pneumococcal pneumonia: is penicillin useful against intermediately resistant strains?, J Antimicrob Chemother, 54, 481, 10.1093/jac/dkh338 Lujan, 2004, Prospective observational study of bacteremic pneumococcal pneumonia: Effect of discordant therapy on mortality, Crit Care Med, 32, 625, 10.1097/01.CCM.0000114817.58194.BF Plouffe, 2003, Azithromycin in the treatment of Legionella pneumonia requiring hospitalization, Clin Infect Dis, 37, 1475, 10.1086/379329 Sabria, 2005, Fluoroquinolones vs macrolides in the treatment of Legionnaires disease, Chest, 128, 1401, 10.1378/chest.128.3.1401 Yu, 2004, Levofloxacin efficacy in the treatment of community‐acquired legionellosis, Chest, 125, 2135, 10.1378/chest.125.6.2135 Capelastegui, 2008, Declining length of hospital stay for pneumonia and postdischarge outcomes, Am J Med, 121, 845, 10.1016/j.amjmed.2008.05.010 Jasti, 2008, Causes and risk factors for rehospitalization of patients hospitalized with community‐acquired pneumonia, Clin Infect Dis, 46, 550, 10.1086/526526 Yende, 2008, Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis, Am J Respir Crit Care Med, 177, 1242, 10.1164/rccm.200712-1777OC Chastre, 2003, Comparison of 8 vs 15 days of antibiotic therapy for ventilator‐associated pneumonia in adults: a randomized trial, JAMA, 290, 2588, 10.1001/jama.290.19.2588 Christ‐Crain, 2006, Procalcitonin guidance of antibiotic therapy in community‐acquired pneumonia: a randomized trial, Am J Respir Crit Care Med, 174, 84, 10.1164/rccm.200512-1922OC Kristoffersen, 2009, Antibiotic treatment interruption of suspected lower respiratory tract infections based on a single procalcitonin measurement at hospital admission – a randomized trial, Clin Microbiol Infect, 15, 481, 10.1111/j.1469-0691.2009.02709.x Schuetz, 2009, Effect of procalcitonin‐based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial, JAMA, 302, 1059, 10.1001/jama.2009.1297 Bouadma, 2010, Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial, Lancet, 375, 463, 10.1016/S0140-6736(09)61879-1 Nobre, 2008, Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial, Am J Respir Crit Care Med, 177, 498, 10.1164/rccm.200708-1238OC Athanassa, 2008, Early switch to oral treatment in patients with moderate to severe community‐acquired pneumonia: a meta‐analysis, Drugs, 68, 2469, 10.2165/0003495-200868170-00005 Lee, 2007, Early switch to oral antibiotics and early discharge guidelines in the management of community‐acquired pneumonia, Respirology, 12, 111, 10.1111/j.1440-1843.2006.00931.x Marras, 2004, Efficacy of exclusively oral antibiotic therapy in patients hospitalized with nonsevere community‐acquired pneumonia: a retrospective study and meta‐analysis, Am J Med, 116, 385, 10.1016/j.amjmed.2003.11.013 van der Eerden, 2004, Evaluation of an algorithm for switching from IV to PO therapy in clinical practice in patients with community‐acquired pneumonia, Clin Ther, 26, 294, 10.1016/S0149-2918(04)90028-8 Shindo, 2008, Implication of clinical pathway care for community‐acquired pneumonia in a community hospital: early switch from an intravenous beta‐lactam plus a macrolide to an oral respiratory fluoroquinolone, Intern Med, 47, 1865, 10.2169/internalmedicine.47.1343 Nathan, 2006, In‐hospital observation after antibiotic switch in pneumonia: a national evaluation, Am J Med, 119, 512, 10.1016/j.amjmed.2005.09.012 Oosterheert, 2006, Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial, BMJ, 333, 1193, 10.1136/bmj.38993.560984.BE Mundy, 2003, Early mobilization of patients hospitalized with community‐acquired pneumonia, Chest, 124, 883, 10.1378/chest.124.3.883 Confalonieri, 1999, Acute respiratory failure in patients with severe community‐acquired pneumonia. A prospective randomized evaluation of noninvasive ventilation, Am J Respir Crit Care Med, 160, 1585, 10.1164/ajrccm.160.5.9903015 Ferrer, 2003, Noninvasive ventilation in severe hypoxemic respiratory failure: a randomized clinical trial, Am J Respir Crit Care Med, 168, 1438, 10.1164/rccm.200301-072OC Antonelli, 2007, A multiple‐center survey on the use in clinical practice of noninvasive ventilation as a first‐line intervention for acute respiratory distress syndrome, Crit Care Med, 35, 18, 10.1097/01.CCM.0000251821.44259.F3 Bulow, 2009, Non‐invasive ventilation in do‐not‐intubate patients: five‐year follow‐up on a two‐year prospective, consecutive cohort study, Acta Anaesthesiol Scand, 53, 1153, 10.1111/j.1399-6576.2009.02034.x Confalonieri, 2005, Hydrocortisone infusion for severe community‐acquired pneumonia: a preliminary randomized study, Am J Respir Crit Care Med, 171, 242, 10.1164/rccm.200406-808OC Gorman, 2007, Corticosteroid treatment of severe community‐acquired pneumonia, Ann Pharmacother, 41, 1233, 10.1345/aph.1H660 Salluh, 2008, The role of corticosteroids in severe community‐acquired pneumonia: a systematic review, Crit Care, 12, R76, 10.1186/cc6922 Siempos, 2008, Adjunctive therapies for community‐acquired pneumonia: a systematic review, J Antimicrob Chemother, 62, 661, 10.1093/jac/dkn283 Adams, 1997, The value of the lipid‐laden macrophage index in the assessment of aspiration pneumonia, Aust N Z J Med, 27, 550, 10.1111/j.1445-5994.1997.tb00963.x Chen, 2006, Occurrence and treatment of suspected pneumonia in long‐term care residents dying with advanced dementia, J Am Geriatr Soc, 54, 290, 10.1111/j.1532-5415.2005.00524.x DeToledo, 2004, Risk of aspiration pneumonia after an epileptic seizure: a retrospective analysis of 1634 adult patients, Epilepsy Behav, 5, 593, 10.1016/j.yebeh.2004.03.009 Kadowaki, 2005, Reappraisal of clindamycin IV monotherapy for treatment of mild‐to‐moderate aspiration pneumonia in elderly patients, Chest, 127, 1276, 10.1378/chest.127.4.1276 Mier, 1993, Is penicillin G an adequate initial treatment for aspiration pneumonia? A prospective evaluation using a protected specimen brush and quantitative cultures, Intensive Care Med, 19, 279, 10.1007/BF01690548 Mylotte, 2003, Pneumonia versus aspiration pneumonitis in nursing home residents: diagnosis and management, J Am Geriatr Soc, 51, 17, 10.1034/j.1601-5215.2002.51004.x Reza, 2006, Differences in the features of aspiration pneumonia according to site of acquisition: community or continuing care facility, J Am Geriatr Soc, 54, 296, 10.1111/j.1532-5415.2005.00608.x Teramoto, 2008, High incidence of aspiration pneumonia in community‐ and hospital‐acquired pneumonia in hospitalized patients: a multicenter, prospective study in Japan, J Am Geriatr Soc, 56, 577, 10.1111/j.1532-5415.2008.01597.x Allewelt, 2004, Ampicillin + sulbactam vs clindamycin +/− cephalosporin for the treatment of aspiration pneumonia and primary lung abscess, Clin Microbiol Infect, 10, 163, 10.1111/j.1469-0691.2004.00774.x Bartlett, 1975, Treatment of aspiration pneumonia and primary lung abscess. Penicillin G vs clindamycin, JAMA, 234, 935, 10.1001/jama.1975.03260220039016 Fernandez‐Sabe, 2003, Efficacy and safety of sequential amoxicillin‐clavulanate in the treatment of anaerobic lung infections, Eur J Clin Microbiol Infect Dis, 22, 185, 10.1007/s10096-003-0898-2 Gudiol, 1990, Clindamycin vs penicillin for anaerobic lung infections. High rate of penicillin failures associated with penicillin‐resistant Bacteroides melaninogenicus, Arch Intern Med, 150, 2525, 10.1001/archinte.1990.00390230077010 Perlino, 1981, Metronidazole vs clindamycin treatment of anerobic pulmonary infection. Failure of metronidazole therapy, Arch Intern Med, 141, 1424, 10.1001/archinte.1981.00340120032009 Ott, 2008, Moxifloxacin vs ampicillin/sulbactam in aspiration pneumonia and primary lung abscess, Infection, 36, 23, 10.1007/s15010-007-7043-6 Chen, 2009, Repeated pneumonia severity index measurement after admission increases its predictive value for mortality in severe community‐acquired pneumonia, J Formos Med Assoc, 108, 219, 10.1016/S0929-6646(09)60055-3 Menendez, 2008, Markers of treatment failure in hospitalised community acquired pneumonia, Thorax, 63, 447, 10.1136/thx.2007.086785 Chalmers, 2008, C‐reactive protein is an independent predictor of severity in community‐acquired pneumonia, Am J Med, 121, 219, 10.1016/j.amjmed.2007.10.033 Coelho, 2007, Usefulness of C‐reactive protein in monitoring the severe community‐acquired pneumonia clinical course, Crit Care, 11, R92, 10.1186/cc6105 Lieberman, 2003, Prevalence and clinical significance of fever in acute exacerbations of chronic obstructive pulmonary disease, Eur J Clin Microbiol Infect Dis, 22, 75, 10.1007/s10096-002-0872-4 Allegra, 2005, Sputum color as a marker of acute bacterial exacerbations of chronic obstructive pulmonary disease, Respir Med, 99, 742, 10.1016/j.rmed.2004.10.020 Soler, 2007, Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease, Thorax, 62, 29, 10.1136/thx.2005.056374 Brusse‐Keizer, 2009, Relation of sputum colour to bacterial load in acute exacerbations of COPD, Respir Med, 103, 601, 10.1016/j.rmed.2008.10.012 Burley, 2007, Indicators of bacterial infection in patients with acute exacerbation of chronic bronchitis for application in clinical trials of antibacterial drugs, J Infect, 55, 226, 10.1016/j.jinf.2007.05.181 Stolz, 2007, Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin‐guidance with standard therapy, Chest, 131, 9, 10.1378/chest.06-1500 Rohde, 2003, Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case‐control study, Thorax, 58, 37, 10.1136/thorax.58.1.37 Lieberman, 2002, Serological evidence ofMycoplasma pneumoniae infection in acute exacerbation of COPD, Diagn Microbiol Infect Dis, 44, 1, 10.1016/S0732-8893(02)00421-2 Groenewegen, 2003, Bacterial infections in patients requiring admission for an acute exacerbation of COPD; a 1‐year prospective study, Respir Med, 97, 770, 10.1016/S0954-6111(03)00026-X Ko, 2005, Sputum bacteriology in patients with acute exacerbations of COPD in Hong Kong, Respir Med, 99, 454, 10.1016/j.rmed.2004.09.011 Rosell, 2005, Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease, Arch Intern Med, 165, 891, 10.1001/archinte.165.8.891 Lin, 2007, Sputum bacteriology in hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease in Taiwan with an emphasis onKlebsiella pneumoniae andPseudomonas aeruginosa, Respirology, 12, 81, 10.1111/j.1440-1843.2006.00999.x Montero, 2009, Mortality of COPD patients infected with multi‐resistantPseudomonas aeruginosa: a case and control study, Infection, 37, 16, 10.1007/s15010-008-8125-9 Lode, 2007, A prediction model for bacterial etiology in acute exacerbations of COPD, Infection, 35, 143, 10.1007/s15010-007-6078-z Garcia‐Vidal, 2009, Pseudomonas aeruginosa in patients hospitalised for COPD exacerbation: a prospective study, Eur Respir J, 34, 1072, 10.1183/09031936.00003309 Kahn, 2007, Study entry microbiology in patients with acute bacterial exacerbation of chronic bronchitis in a clinical trial stratifying by disease severity, Curr Med Res Opin, 23, 1, 10.1185/030079907X159515 Murphy, 2005, Moraxella catarrhalis in chronic obstructive pulmonary disease: burden of disease and immune response, Am J Respir Crit Care Med, 172, 195, 10.1164/rccm.200412-1747OC Murphy, 2004, Persistent colonization byHaemophilus influenzae in chronic obstructive pulmonary disease, Am J Respir Crit Care Med, 170, 266, 10.1164/rccm.200403-354OC Papi, 2006, Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations, Am J Respir Crit Care Med, 173, 1114, 10.1164/rccm.200506-859OC Wilkinson, 2003, Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease, Am J Respir Crit Care Med, 167, 1090, 10.1164/rccm.200210-1179OC Sethi, 2007, Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease, Am J Respir Crit Care Med, 176, 356, 10.1164/rccm.200703-417OC Sethi, 2004, Strain‐specific immune response toHaemophilus influenzae in chronic obstructive pulmonary disease, Am J Respir Crit Care Med, 169, 448, 10.1164/rccm.200308-1181OC Aaron, 2004, Sputum versus bronchoscopy for diagnosis ofPseudomonas aeruginosa biofilms in cystic fibrosis, Eur Respir J, 24, 631, 10.1183/09031936.04.00049104 Wilson, 2003, Oral gemifloxacin once daily for 5 days compared with sequential therapy with i.v. ceftriaxone/oral cefuroxime (maximum of 10 days) in the treatment of hospitalized patients with acute exacerbations of chronic bronchitis, Respir Med, 97, 242, 10.1053/rmed.2003.1435 Martinez, 2005, Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis: the role of levofloxacin 750 mg, Eur Respir J, 25, 1001, 10.1183/09031936.05.00106404 Dimopoulos, 2007, Comparison of first‐line with second‐line antibiotics for acute exacerbations of chronic bronchitis: a metaanalysis of randomized controlled trials, Chest, 132, 447, 10.1378/chest.07-0149 Ferrer, 2005, Microbial airway colonization is associated with noninvasive ventilation failure in exacerbation of chronic obstructive pulmonary disease, Crit Care Med, 33, 2003, 10.1097/01.CCM.0000178185.50422.DB Bilton, 2006, Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations ofPseudomonas aeruginosa infection in adult bronchiectasis, Chest, 130, 1503, 10.1378/chest.130.5.1503 Evans, 2003, Prolonged antibiotics for purulent bronchiectasis, Cochrane Database Syst Rev, 4 Cogo, 2003, Prophylaxis for acute exacerbations of chronic bronchitis using an antibacterial sublingual vaccine obtained through mechanical lysis: a clinical and pharmacoeconomic study, Acta Biomed Ateneo Parmense, 74, 81 Foxwell, 2003, Haemophilus influenzae oral whole cell vaccination for preventing acute exacerbations of chronic bronchitis, Cochrane Database Syst Rev, 3, 10.1002/14651858.CD001958 Steurer‐Stey, 2004, Oral purified bacterial extracts in chronic bronchitis and COPD: systematic review, Chest, 126, 1645, 10.1378/chest.126.5.1645 Tricarico, 2004, Prevention of recurrent upper respiratory tract infections in a community of cloistered nuns using a new immunostimulating bacterial lysate. A randomized, double‐blind clinical trial, Arzneimittelforschung, 54, 57 Black, 2003, Prophylactic antibiotic therapy for chronic bronchitis, Cochrane Database Syst Rev, 1 Smucny, 2004, Antibiotics for acute bronchitis, Cochrane Database Syst Rev, 4, 10.1002/14651858.CD001726.pub2 Sethi, 2010, Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial, Respir Res, 11, 10, 10.1186/1465-9921-11-10 Seemungal, 2008, Long‐term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations 86, Am J Respir Crit Care Med, 178, 1139, 10.1164/rccm.200801-145OC Drobnic, 2005, Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection withPseudomonas aeruginosa, Ann Pharmacother, 39, 39, 10.1345/aph.1E099 Barker, 2000, Tobramycin solution for inhalation reduces sputumPseudomonas aeruginosa density in bronchiectasis, Am J Respir Crit Care Med, 162, 481, 10.1164/ajrccm.162.2.9910086 Cymbala, 2005, The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis, Treat Respir Med, 4, 117, 10.2165/00151829-200504020-00005 Anwar, 2008, Effects of long‐term low‐dose azithromycin in patients with non‐CF bronchiectasis 232, Respir Med, 102, 1494, 10.1016/j.rmed.2008.06.005 Nordstrom, 2005, Risk of pneumonia and other complications of influenza‐like illness in patients treated with oseltamivir, Curr Med Res Opin, 21, 761, 10.1185/030079905X46214 Poole, 2006, Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease, Cochrane Database Syst Rev, 3, 10.1002/14651858.CD001287.pub2 Douglas, 2004, Vitamin C for preventing and treating the common cold, Cochrane Database Syst Rev, 4, 10.1002/14651858.CD000980.pub2 Barrett, 2002, Treatment of the common cold with unrefined echinacea. A randomized, double‐blind, placebo‐controlled trial, Ann Intern Med, 137, 939, 10.7326/0003-4819-137-12-200212170-00006 McElhaney, 2006, Efficacy of COLD‐fX in the prevention of respiratory symptoms in community‐dwelling adults: a randomized, double‐blinded, placebo controlled trial, J Altern Complement Med, 12, 153, 10.1089/acm.2006.12.153 Sjogren, 2008, A systematic review of the preventive effect of oral hygiene on pneumonia and respiratory tract infection in elderly people in hospitals and nursing homes: effect estimates and methodological quality of randomized controlled trials, J Am Geriatr Soc, 56, 2124, 10.1111/j.1532-5415.2008.01926.x Awano, 2008, Oral health and mortality risk from pneumonia in the elderly, J Dent Res, 87, 334, 10.1177/154405910808700418 Bassim, 2008, Modification of the risk of mortality from pneumonia with oral hygiene care, J Am Geriatr Soc, 56, 1601, 10.1111/j.1532-5415.2008.01825.x Singh, 2009, Long‐term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta‐analysis, Arch Intern Med, 169, 219, 10.1001/archinternmed.2008.550 Almirall, 2008, New evidence of risk factors for community‐acquired pneumonia: a population‐based study, Eur Respir J, 31, 1274, 10.1183/09031936.00095807 Ernst, 2007, Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia, Am J Respir Crit Care Med, 176, 162, 10.1164/rccm.200611-1630OC Drummond, 2008, Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta‐analysis, JAMA, 300, 2407, 10.1001/jama.2008.717 Sin, 2009, Budesonide and the risk of pneumonia: a meta‐analysis of individual patient data, Lancet, 374, 712, 10.1016/S0140-6736(09)61250-2 Mortensen, 2008, Impact of statins and angiotensin‐converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia, Eur Respir J, 31, 611, 10.1183/09031936.00162006 Chalmers, 2008, Prior statin use is associated with improved outcomes in community‐acquired pneumonia, Am J Med, 121, 1002, 10.1016/j.amjmed.2008.06.030 Dublin, 2009, Statin use and risk of community acquired pneumonia in older people: population based case‐control study, BMJ, 338, b2137, 10.1136/bmj.b2137 Schlienger, 2007, Statins and the risk of pneumonia: a population‐based, nested case‐control study, Pharmacotherapy, 27, 325, 10.1592/phco.27.3.325 Thomsen, 2008, Preadmission use of statins and outcomes after hospitalization with pneumonia: population‐based cohort study of 29,900 patients, Arch Intern Med, 168, 2081, 10.1001/archinte.168.19.2081 Tleyjeh, 2009, Statins for the prevention and treatment of infections: a systematic review and meta‐analysis, Arch Intern Med, 169, 1658, 10.1001/archinternmed.2009.286 Hak, 2005, Clinical effectiveness of influenza vaccination in persons younger than 65 years with high‐risk medical conditions: the PRISMA study, Arch Intern Med, 165, 274, 10.1001/archinte.165.3.274 Hak, 2003, Conventional influenza vaccination is not associated with complications in working‐age patients with asthma or chronic obstructive pulmonary disease, Am J Epidemiol, 157, 692, 10.1093/aje/kwg027 Schembri, 2009, Influenza but not pneumococcal vaccination protects against all‐cause mortality in patients with COPD, Thorax, 64, 567, 10.1136/thx.2008.106286 Ortqvist, 2007, Influenza vaccination and mortality: prospective cohort study of the elderly in a large geographical area, Eur Respir J, 30, 414, 10.1183/09031936.00135306 Jackson, 2006, Evidence of bias in estimates of influenza vaccine effectiveness in seniors, Int J Epidemiol, 35, 337, 10.1093/ije/dyi274 Eurich, 2008, Mortality reduction with influenza vaccine in patients with pneumonia outside “flu” season: pleiotropic benefits or residual confounding?, Am J Respir Crit Care Med, 178, 527, 10.1164/rccm.200802-282OC Jackson, 2008, Influenza vaccination and risk of community‐acquired pneumonia in immunocompetent elderly people: a population‐based, nested case‐control study 181, Lancet, 372, 398, 10.1016/S0140-6736(08)61160-5 Jefferson, 2010, Vaccines for preventing influenza in the elderly, Cochrane Database Syst Rev, 2, 10.1002/14651858.CD001269.pub4 Govaert, 1994, The efficacy of influenza vaccination in elderly individuals. A randomized double‐blind placebo‐controlled trial, JAMA, 272, 1661, 10.1001/jama.1994.03520210045030 Fiore, 2007, Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007, MMWR Recomm Rep, 56, 1 Wang, 2009, Live attenuated or inactivated influenza vaccines and medical encounters for respiratory illnesses among US military personnel, JAMA, 301, 945, 10.1001/jama.2009.265 Monto, 2009, Comparative efficacy of inactivated and live attenuated influenza vaccines, N Engl J Med, 361, 1260, 10.1056/NEJMoa0808652 Nichol, 2008, Influenza vaccination among college and university students: impact on influenzalike illness, health care use, and impaired school performance, Arch Pediatr Adolesc Med, 162, 1113, 10.1001/archpedi.162.12.1113 Demicheli, 2004, Vaccines for preventing influenza in healthy adults, Cochrane Database Syst Rev, 3, 10.1002/14651858.CD001269.pub2 Thomas, 2006, Influenza vaccination for healthcare workers who work with the elderly, Cochrane Database Syst Rev, 3, 10.1002/14651858.CD005187.pub2 Thomas, 2010, Influenza vaccination for healthcare workers who work with the elderly, Cochrane Database Syst Rev, 2, 10.1002/14651858.CD005187.pub3 van Kessel, 2005, Impaired pneumococcal antibody response in bronchiectasis of unknown aetiology, Eur Respir J, 25, 482, 10.1183/09031936.05.00073204 Ortqvist, 2007, Non‐response to specific serotypes likely cause for failure to 23‐valent pneumococcal polysaccharide vaccine in the elderly, Vaccine, 25, 2445, 10.1016/j.vaccine.2006.09.018 Abraham‐Van Parijs, 2004, Review of pneumococcal conjugate vaccine in adults: implications on clinical development, Vaccine, 22, 1362, 10.1016/j.vaccine.2004.01.029 Musher, 2008, Initial and subsequent response to pneumococcal polysaccharide and protein‐conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia, J Infect Dis, 198, 1019, 10.1086/591629 de Roux, 2008, Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory, Clin Infect Dis, 46, 1015, 10.1086/529142 Kyaw, 2006, Effect of introduction of the pneumococcal conjugate vaccine on drug‐resistantStreptococcus pneumoniae, N Engl J Med, 354, 1455, 10.1056/NEJMoa051642 Whitney, 2003, Decline in invasive pneumococcal disease after the introduction of protein‐polysaccharide conjugate vaccine, N Engl J Med, 348, 1737, 10.1056/NEJMoa022823 Grijalva, 2007, Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time‐series analysis, Lancet, 369, 1179, 10.1016/S0140-6736(07)60564-9 Nelson, 2008, Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults 211, Vaccine, 26, 4947, 10.1016/j.vaccine.2008.07.016 Melegaro, 2004, The 23‐valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: a comparison of meta‐analyses, Eur J Epidemiol, 19, 353, 10.1023/B:EJEP.0000024701.94769.98 Dear, 2003, Vaccines for preventing pneumococcal infection in adults, Cochrane Database Syst Rev, 4 Conaty, 2004, The effectiveness of pneumococcal polysaccharide vaccines in adults: a systematic review of observational studies and comparison with results from randomised controlled trials, Vaccine, 22, 3214, 10.1016/j.vaccine.2003.08.050 Moberley, 2008, Vaccines for preventing pneumococcal infection in adults, Cochrane Database Syst Rev, 1, 10.1002/14651858.CD000422.pub2 Alfageme, 2006, Clinical efficacy of anti‐pneumococcal vaccination in patients with COPD, Thorax, 61, 189, 10.1136/thx.2005.043323 Jackson, 2003, Effectiveness of pneumococcal polysaccharide vaccine in older adults, N Engl J Med, 348, 1747, 10.1056/NEJMoa022678 Christenson, 2004, Additive preventive effect of influenza and pneumococcal vaccines in elderly persons, Eur Respir J, 23, 363, 10.1183/09031936.04.00063504 Vila‐Corcoles, 2006, Protective effects of the 23‐valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN‐65 study, Clin Infect Dis, 43, 860, 10.1086/507340 Maruyama, 2010, Efficacy of 23‐valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial, BMJ, 340, c1004, 10.1136/bmj.c1004 Christenson, 2008, Effect of influenza and pneumococcal vaccines in elderly persons in years of low influenza activity, Virol J, 5, 52, 10.1186/1743-422X-5-52 Ochoa‐Gondar, 2008, Effectiveness of pneumococcal vaccination in older adults with chronic respiratory diseases: results of the EVAN‐65 study, Vaccine, 26, 1955, 10.1016/j.vaccine.2008.02.021 Lee, 2007, Impact of pneumococcal vaccination on pneumonia rates in patients with COPD and asthma, J Gen Intern Med, 22, 62, 10.1007/s11606-007-0118-3 Skull, 2007, Prevention of community‐acquired pneumonia among a cohort of hospitalized elderly: benefit due to influenza and pneumococcal vaccination not demonstrated, Vaccine, 25, 4631, 10.1016/j.vaccine.2007.03.015 Spindler, 2008, Effects of a large‐scale introduction of the pneumococcal polysaccharide vaccine among elderly persons in Stockholm, Sweden, Vaccine, 26, 5541, 10.1016/j.vaccine.2008.06.073 Mooney, 2008, The impact and effectiveness of pneumococcal vaccination in Scotland for those aged 65 and over during winter 2003/2004, BMC Infect Dis, 8, 53, 10.1186/1471-2334-8-53 Fisman, 2006, Prior pneumococcal vaccination is associated with reduced death, complications, and length of stay among hospitalized adults with community‐acquired pneumonia, Clin Infect Dis, 42, 1093, 10.1086/501354 Mykietiuk, 2006, Effect of prior pneumococcal vaccination on clinical outcome of hospitalized adults with community‐acquired pneumococcal pneumonia, Eur J Clin Microbiol Infect Dis, 25, 457, 10.1007/s10096-006-0161-8 Melegaro, 2004, The 23‐valent pneumococcal polysaccharide vaccine. Part II. A cost‐effectiveness analysis for invasive disease in the elderly in England and Wales, Eur J Epidemiol, 19, 365, 10.1023/B:EJEP.0000024752.48929.bd Mangtani, 2005, An economic analysis of a pneumococcal vaccine programme in people aged over 64 years in a developed country setting, Int J Epidemiol, 34, 565, 10.1093/ije/dyh341 McIntosh, 2005, Pneumococcal pneumonia in the UK – how herd immunity affects the cost‐effectiveness of 7‐valent pneumococcal conjugate vaccine (PCV), Vaccine, 23, 1739, 10.1016/j.vaccine.2004.08.051 Jackson, 2005, Safety of varying dosages of 7‐valent pneumococcal protein conjugate vaccine in seniors previously vaccinated with 23‐valent pneumococcal polysaccharide vaccine, Vaccine, 23, 3697, 10.1016/j.vaccine.2005.02.017 Torling, 2003, Revaccination with the 23‐valent pneumococcal polysaccharide vaccine in middle‐aged and elderly persons previously treated for pneumonia, Vaccine, 22, 96, 10.1016/S0264-410X(03)00521-8 Waites, 2008, Revaccination of adults with spinal cord injury using the 23‐valent pneumococcal polysaccharide vaccine, J Spinal Cord Med, 31, 53, 10.1080/10790268.2008.11753981 Dexter, 2004, Inpatient computer‐based standing orders vs physician reminders to increase influenza and pneumococcal vaccination rates: a randomized trial, JAMA, 292, 2366, 10.1001/jama.292.19.2366 Jacobson, 2005, Patient reminder and patient recall systems to improve immunization rates, Cochrane Database Syst Rev, 3, 10.1002/14651858.CD003941.pub2 deHart, 2005, Project protect: pneumococcal vaccination in Washington State nursing homes, J Am Med Dir Assoc, 6, 91, 10.1016/j.jamda.2005.01.001 Jha, 2007, Performance measures, vaccinations, and pneumonia rates among high‐risk patients in Veterans Administration health care, Am J Public Health, 97, 2167, 10.2105/AJPH.2006.099440